UNSPSC 51152011: Tubocurarine

This classification denotes a nicotinic antagonist and neuromuscular nondepolarizing agent with the molecular formula C37H41N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W9YXS298BM, chemically known as 13h-4,6:21,24-dietheno-8,12-metheno-1h-pyrido(3,2:14,15)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolinium, 2,3,13a,14,15,16,25,25a-octahydro-9,19-dihydroxy-18,29-dimethoxy-1,14,14-trimethyl-, (13ar,25as)- but generally known as tubocurarine, which bears US NIH Compound Identifier 6000.

UNSPSC 51152011 Tubocurarine is a Commodity code that designates a specific pharmaceutical agent used primarily in medical and emergency-response settings. Recent state and local procurement activity under this code shows minimal direct solicitation for tubocurarine itself; instead, issuing bodies are procuring naloxone and drug deactivation systems for public health and emergency-management purposes. Seminole County, Florida, for example, issued an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually to support community health initiatives. The Texas Health and Human Services Commission issued a Request for Information in April 2026 to explore direct-to-manufacturer prescription programs that would expand access to pharmaceutical products beyond traditional pharmacy benefit manager and group purchasing organization channels. State and local governments using this code appear to be county health departments, state HHS agencies, and public-health authorities focused on opioid-response and emergency-medication procurement rather than traditional medical-facility inventory.

The recent opportunities show activity concentrated in Florida and Texas, with the Seminole County solicitation (IFB60459723LAS) requiring quarterly deliveries to Sanford, Florida, and the Texas HHS RFI (HHS0017013) targeting statewide pharmacy-benefit reform. The Seminole County IFB, posted June 30, 2026, with a July 26, 2023 response deadline, sought unit pricing for naloxone and drug deactivation systems under a two-year initial term with one-year renewal option, with no explicit set-asides but requiring E-Verify compliance and federal compliance under potential FEMA funding. The Texas RFI is exploratory rather than a formal competitive solicitation and does not indicate a near-term award. The code shows limited recent activity tied directly to tubocurarine procurement; the mismatch between the code's nominal scope and the actual goods being procured (naloxone and deactivation systems) suggests either coding drift in the state and local system or that tubocurarine itself is rarely solicited independently at the state and local level.